Kapruvia (Difelikefalin)

Difelikefalin is a selective agonist of peripheral kappa opioid receptors. By activating these receptors on sensory nerve endings, it dampens the transmission of itch signals to the brain, thereby reducing the perception of pruritus without producing central opioid effects.

The dosage of Kapruvia is determined by the prescribing clinician based on the individual patient's clinical condition, renal status, and response to therapy. Specific dosing regimens are not publicly disclosed and should be obtained from the treating healthcare professional.

Safety data for Kapruvia during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the prescriber in consultation with the patient.

To request Kapruvia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Kapruvia belongs to the kappa opioid receptor agonist class, which differs from traditional antihistamines or gabapentinoids often used for itch. Compared with those alternatives, difelikefalin targets peripheral opioid receptors directly, offering a mechanism that can be effective when other antipruritics fail, though safety and cost considerations may differ.

Kapruvia must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and do not freeze or shake the product. If temperature excursions occur, consult the supplier before use.

Kapruvia is supplied as an intravenous injection. It is administered by a qualified healthcare professional, typically as an infusion over a short period during a hemodialysis session, according to the prescribing information and institutional protocols.

The most serious adverse events include severe hypersensitivity reactions such as anaphylaxis, marked hypotension, and respiratory depression. Patients should be monitored for signs of allergic response, sudden drops in blood pressure, or difficulty breathing, and treatment should be stopped immediately if these occur.

Kapruvia is contraindicated in individuals with known hypersensitivity to difelikefalin or any component of the formulation. Caution is also advised for patients with severe cardiovascular instability or those receiving other kappa opioid agonists, as additive effects may increase risk.